Article
Urology & Nephrology
Ian M. McElree, Vignesh T. Packiam, Ryan L. Steinberg, Sarah L. Mott, Paul T. Gellhaus, Kenneth G. Nepple, Michael A. O'Donnell
Summary: Valrubicin and docetaxel have shown to be an effective rescue therapy for recurrent non-muscle-invasive bladder cancer.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Ian M. McElree, Ryan L. Steinberg, Alex C. Martin, Jordan Richards, Sarah L. Mott, Paul T. Gellhaus, Kenneth G. Nepple, Michael A. O'Donnell, Vignesh T. Packiam
Summary: This study retrospectively analyzed the outcomes of patients with high-risk BCG-naive NMIBC treated with Gem/Doce and found that Gem/Doce was an effective and well-tolerated therapy.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Eduardo Moreo, Santiago Uranga, Ana Pico, Ana Belen Gomez, Denise Nardelli-Haefliger, Carlos del Fresno, Ingrid Murillo, Eugenia Puentes, Esteban Rodriguez, Mar Vales-Gomez, Julian Pardo, David Sancho, Carlos Martin, Nacho Aguilo
Summary: By comparing the antitumoral efficacy of BCG and MTBVAC in a mouse model, this study found that MTBVAC can enhance bladder colonization by expressing specific absent proteins and stimulate cytotoxic responses to improve immune response against tumor antigens. Furthermore, intravesical bacterial immunotherapy using MTBVAC can lead to complete eradication of bladder tumors, either as a monotherapy or in combination with immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, General & Internal
Kuo-Wei Kao, Weiming Cheng, Yi-Chin Chang
Summary: Bladder chondroma is a rare benign tumor that mainly affects older patients. It manifests as urinary symptoms and abdominal pain, and transurethral resection is the preferred treatment.
Article
Pharmacology & Pharmacy
You Li, Shams F. Youssef, Asma B. M. Buanz
Summary: Bladder cancer is one of the top ten most commonly diagnosed cancers globally, with limited treatment options, but the development of intravesical combination therapies offers hope for overcoming treatment failures, although limitations still need to be addressed.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Pooja Jain, Himanshu Kathuria, Munira Momin
Summary: Bladder cancer is the 10th most common malignancy worldwide with a 5-year survival rate of 75%, but 70% of the cases develop chemoresistance and progress to the muscle invasive stage. Nanotechnology has shown promise in targeted drug delivery to bladder cancer cells, offering potential for better treatment management.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Instruments & Instrumentation
Abhijit A. Date, Max Kates, Takahiro Yoshida, Taarika Babu, Umara Afzal, Pranjali Kanvinde, Alexander Baras, Nicole Anders, Ping He, Michelle Rudek, Justin Hanes, Trinity J. Bivalacqua, Laura M. Ensign
Summary: The study demonstrates that the combination of nanoparticle-based chemotherapy and a hypotonic vehicle can provide more effective local drug delivery to bladder tissue for improved treatment of refractory NMIBC.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2021)
Article
Oncology
Jelmer H. van Puffelen, Boris Novakovic, Liesbeth van Emst, Denise Kooper, Tahlita C. M. Zuiverloon, Ursula T. H. Oldenhof, J. Alfred Witjes, Tessel E. Galesloot, Alina Vrieling, Katja K. H. Aben, Lambertus A. L. M. Kiemeney, Egbert Oosterwijk, Mihai G. Netea, Joost L. Boormans, Antoine G. van der Heijden, Leo A. B. Joosten, Sita H. Vermeulen
Summary: This study found that intravesical BCG immunotherapy induces trained immunity in NMIBC patients, which can reduce the risk of respiratory infections.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Chin-Li Chen, Chien-Chang Kao, Ming-Hsin Yang, Gang-Yi Fan, Juin-Hong Cherng, Chih-Wei Tsao, Sheng-Tang Wu, Tai-Lung Cha, En Meng
Summary: The study demonstrated that dextrose prolotherapy shows promising treatment results for IC/BPS, reducing bladder instability, frequent urination, improving glycosaminoglycan layer regeneration and bladder wall thickness, along with significantly enhancing CD44 receptor expression. Additionally, it reduced treatment frequency over time and improved EGF levels while reducing HGF, PIGF-1, and VEGF-D levels in patients with IC/BPS. The modulation of growth factors and cytokines suggests potential tissue remodeling effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Vanessa Bellat, Adam O. Michel, Charlene Thomas, Tracy Stokol, Benjamin B. Choi, Benedict Law
Summary: The standard treatment for nonmuscle invasive bladder cancer (NMIBC) still faces challenges such as high recurrence rate, invasiveness, pain, and infection risk. This study developed a urinary drug-disposing (UDD) approach that utilizes renal clearance to deliver drugs to bladder tumors, improving NMIBC treatment. The UDD approach showed prolonged survival in mice with bladder tumors and demonstrated higher efficacy in suppressing tumor growth compared to current clinical treatments.
Article
Oncology
Niannian Ji, Neelam Mukherjee, Ryan M. Reyes, Jonathan Gelfond, Martin Javors, Joshua J. Meeks, David J. McConkey, Zhen-Ju Shu, Chethan Ramamurthy, Ryan Dennett, Tyler J. Curiel, Robert S. Svatek
Summary: The combination of oral rapamycin with BCG treatment for NMIBC patients is safe and well-tolerated, enhancing BCG-specific gamma delta T cell immunity and increasing urinary cytokines during BCG treatment. Further research is necessary to explore the long-term safety, tolerability, and efficacy effects of rapamycin in conjunction with BCG.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Jia-Fong Jhang, Han-Chen Ho, Yuan-Hsiang Hsu, Yuan-Hong Jiang, Hann-Chorng Kuo
Summary: This study found that patients with recurrent urinary tract infection (rUTI) have bladder defects and elevated urine inflammatory markers. After treatment with platelet-rich plasma (PRP) injections, some patients showed improvement in bladder defects.
Review
Pharmacology & Pharmacy
Muhammad Sarfraz, Shaista Qamar, Masood Ur Rehman, Muhammad Azam Tahir, Muhammad Ijaz, Anam Ahsan, Mulazim Hussain Asim, Imran Nazir
Summary: Intravesical drug delivery is a direct approach for treating bladder diseases with site-specific drug action. However, there are limitations such as washout of drugs and poor permeability. Nanomaterial-based delivery systems are being used to enhance drug penetration and retention in the bladder, improving treatment efficacy.
Review
Urology & Nephrology
Michael Nazmifar, Cheyenne Williams, Aurash Naser-Tavakolian, John Heard, Charles Rosser, Dan Theodorescu, Michael Ahdoot
Summary: The purpose of this study is to evaluate the efficacy of various therapeutic agents for high-grade nonmuscle-invasive bladder cancer following failed bacillus Calmette-Guerin treatment. A systematic review of available clinical trials was conducted, and a total of 70 studies evaluating 27 treatment options were analyzed. Intravesical chemotherapy and hyperthermia paired with chemotherapy demonstrated high complete response rates, while immunotherapy and novel agents also showed promising results. The treatments had low toxicity profiles and complication rates.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Christopher J. Chermansky, Holly E. Richter, Karny Jacoby, Wilson Titanji, Brenda Jenkins, Till Geib, Benjamin M. Brucker
Summary: The intravesical instillation of an onabotulinumtoxinA + D hydrogel admixture for refractory overactive bladder was well tolerated but did not show improvement over placebo in reducing urinary incontinence episodes. Treatment-emergent adverse events were similar among all groups, with asymptomatic bacteriuria being the most common reported.
JOURNAL OF UROLOGY
(2022)